Interleukin-23 Monoclonal Antibody for Inflammatory Bowel Disease: Efficacy and Safety

NCT07216014 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Crohn's Disease and Ulcerative Colitis

Interventions

DRUG: Interleukin 23
DEVICE: Interleukin 23

Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University